Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
DocMorris ( (CH:DOCM) ) has provided an announcement.
The Federal Court of Justice (BGH) has overturned a previous ruling prohibiting prescription bonuses, aligning with the European Court of Justice’s stance that such bonuses are permissible under EU law. This decision allows DocMorris to reintroduce cash bonuses for prescription medications, reducing patient costs and potentially enhancing its competitive position in the online pharmacy market.
The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF15.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris AG is a prominent player in the online pharmacy and healthcare marketplace sectors, with a significant presence in Germany and other European countries. The company operates a highly automated logistics center in the Netherlands and leads marketplaces for health products in Spain and France. With a vision to create a digital health ecosystem, DocMorris serves over 10 million active customers and is listed on the SIX Swiss Exchange.
Average Trading Volume: 532,152
Current Market Cap: CHF370.4M
Learn more about DOCM stock on TipRanks’ Stock Analysis page.